Molsidomine: Alternative Approaches To Treat Myocardial Ischemia

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 7, Issue 1, 1987, Pages 28-37

  Nitz, Rolf‐Eberhard ^a   Fiedler, Volker B ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MOLSIDOMINE;

ANIMAL EXPERIMENT; BLOOD AND HEMOPOIETIC SYSTEM; DOG; DRUG ADMINISTRATION; DRUG DOSE; DRUG METABOLISM; DRUG THERAPY; GREAT BLOOD VESSEL; HEART; HEART INFARCTION; ISCHEMIC HEART DISEASE; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGY; PRELIMINARY COMMUNICATION; PRIORITY JOURNAL; REVIEW; THERAPY; THROMBOCYTE AGGREGATION;

EID: 0023146958     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1987.tb03503.x     Document Type: Article

References (145)

1. Can drugs really limit infarct size?
2. Protection of the ischemic myocardium
3. Why are we still in doubt about infarct size limitation? The experimentalist's viewpoint
4. Observations on experimental myocardial ischaemia
5. Control of myocardial oxygen consumption: physiologic and clinical considerations
6. Factors influencing infarct size following coronary artery occlusion
7. Hemodynamic determinants of oxygen consumption of the heart with special references to the tension‐time index
8. Treatment of the patient after myocardial infarction
9. Surgery for evolving myocardial infarction
10. Role of delayed intraaortic balloon pumping in treatment of experimental myocardial infarction
11. Reduction of ischemic injury by nitroglycerin during acute myocardial infarction
12. On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs
13. Comparison of five beta‐adrenoceptor antagonists with different ancillary properties during sustained twice‐daily therapy in angina pectoris
14. Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction
15. Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs
16. Effects of nifedipine on myocardial perfusion and ischemic injury in dogs
17. Calcium and acute myocardial infarction
18. Reduction of CK and CK‐MB indexes of infarct size by intravenous nitroglycerin
19. Effects of oral carbocromene pretreatment on infarct size following experimental coronary artery occlusion
20. A rationale for therapy of acute myocardial infarction: limitation of infarct size
21. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction
22. On the limitation of therapeutic intervention trials in ischemic heart disease: a clinician's viewpoint
23. The management of acute myocardial infarction
24. A comparative study of cardioselective β‐blockade and diazepam in patients with acute myocardial infarction and tachycardia
25. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog
26. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by antiinflammatory drugs
27. Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size
28. Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease
29. The salvage of ischaemic myocardium by BW 755C in anaesthetized dogs
30. The effects of nafazatrom in an acute occlusion‐reperfusion model of canine myocardial injury
31. Leukocytes and ischemia‐induced myocardial injury
32. The arachidonic acid metabolic capacity of canine myocardium is increased during healing of acute myocardial infarction
33. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog
34. Inhibition of polymorphonuclear leukocyte functions by chlortetracycline
35. The effect of ibuprofen on accumulation of indium‐111‐labeled platelets and leukocytes in experimental myocardial infarction
36. Influence of sulfinpyrazone and naproxen on infarct size in the dog
37. Effect of zomepirac on experimental coronary artery thrombosis and ischemic myocardial injury in the conscious dog
38. Role of polymorphonuclear leukocytes in the vascular responses of acute inflammation
39. Platelet trapping in myocardial infarct in baboons: therapeutic effect of aspirin
40. Modulation of inflammatory reactions by prostaglandins
41. Über Sydnonimine. I. Herstellung und Eigenschaften von Sydnonimin‐Salzen
42. Molsidomine ‐ an effective antianginal drug. Results of an acute randomized stress‐testing study
43. Molsidomine in the treatment of patients with angina pectoris. Acute hemodynamic effects and clinical efficacy
44. Metabolic fate of 5‐ethoxycarbonyl‐3‐morpholinosydnonimine (SIN‐10). 1. Absorption, excretion and tissue distribution in rats and mice
45. Biotransformation of molsidomine (N‐ethoxycarbonyl‐3‐morpholinosydnonimine), a new anti‐anginal agent, in rats
46. Hemodynamic and myocardial effects of long‐lasting venodilation in the conscious dog: analysis of molsidomine in comparison with nitrates
47. Increased effective vascular compliance and venous pooling of intravascular volume during sustained venodilation in conscious dogs
48. Comparative study of nitroglycerin and molsidomine. Effects on the integrated systemic venous bed and the arterial pressure in dogs
49. Effect of molsidomine on cardiac preload, coronary artery diameter, and coronary resistance
50. Active and passive changes in coronary diameter after vasodilation with SIN‐1, the active metabolite of molsidomine
51. Die Wirkung von Molsidomin auf die regionale Verteilung des Herzminutenvolumens des narkotisierten Hundes
52. 2 formation
53. The effects of molsidomine and its metabolite SIN‐1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro. Inhibition of 12‐HPETE biosynthesis
54. Molsidomine on cardiovascular leukotriene D4 actions
55. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites
56. Molsidomin, Koronartherapeutikum mit plättchenaggregationshemmender Wirkung
57. Reduction of occlusive coronary artery thrombosis and myocardial ischemia by molsidomine in anesthetized dogs
58. Comparison of the effect of molsidomine, nitroglycerin and isosorbide dinitrate on experimentally induced coronary artery thrombosis in the dog
59. Die Wirkung von Molsidomin und Nitroglycerin auf die regionale Durchblutung des normalen und akutischämischen Myokards
60. Effect of molsidomine on coronary collateral blood flow in acute myocardial ischemia
61. Comparison of various methods for assessing infarct size in the dog
62. Effects of molsidomine and dopamine infusion on the size of canine experimental myocardial infarct
63. Unloading effects of molsidomine on peripheral circulation and cardiac hemodynamics in patients with acute myocardial infarction
64. Hemodynamic effects of molsidomine in patients with acute myocardial infarction
65. Cardiovascular pharmacology of molsidomine
66. Haemodynamic effects of molsidomine
67. Molsidomine
68. Molsidomine
69. Pharmakologische Basis der Therapie mit Molsidomin
70. Effects of molsidomine on the coronary circulation in anesthetized dogs
71. Analysis of oral molsidomine effects on ventricular function and dimensions in the conscious dog
72. Hämodynamische Wirkungen von Molsidomin bei koronarer Herzerkrankung
73. The mode of hypotensive action of newly synthesized sydnonimine derivatives
74. Hypotensive effect of N‐ethoxycarbonyl‐3‐morpholinosydnonimine (SIN‐10) in carbon tetrachloride‐treated rats
75. Femoral collateral vasodilator action of a new antianginal agent, molsidomine, in the dog
76. Haemodynamic effects of molsidomin
77. Hypotensive action of N‐ethoxycarbonyl‐3‐morpholinosydnonimine, SIN‐10
78. Cardiovascular action of mesoionic compounds, 3‐substituted sydnonimines
79. Die Wirkung von Molsidomin auf den arteriellen Windkessel
80. Effects of N‐ethoxycarbonyl‐3‐morpholinosydnonimine (SIN‐10) on the cardiovascular system
81. Zur Pharmakologie von Sydnonen und Sydnoniminen
82. Determination of left ventricular dimensions with ultrasound
83. 2‐Bedarfes des Herzmuskels
84. Coronary collateral vasodilator action of N‐ethoxycarbonyl‐3‐morpholinosydnonimine (SIN‐10) in heart with chronic coronary insufficiency in dogs
85. Einfluss von Molsidomin auf Parameter des Niederdrucksystems. Hämodynamische, venenverschluss‐plethysmographische und szintigraphische Untersuchungen
86. Evaluation of the chronic antianginal effect of molsidomine
87. Effects of molsidomine on hemodynamics and blood gases in acute myocardial infarction with left heart failure
88. Effects of molsidomine, nitroglycerin, and isosorbide dinitrate on the coronary circulation, myocardial oxygen consumption, and haemodynamics in anaesthetized dogs
89. The antianginal effect of molsidomine in prolonged oral therapy. A double‐blind, crossover, randomized study
90. The dependence of coronary collateral blood flow on regional vascular resistances. Pharmacological studies with glyceryl trinitrate, adenosine and verapamil
91. Vasorelaxing actions of molsidomine and its metabolites, in comparison with nitroglycerin
92. Angina pectoris and chronic congestive heart failure: pathophysiology and therapy
93. Combined dopamine and nitroprusside therapy in congestive heart failure. Greater augmentation of cardiac performance by addition of inotropic stimulation to afterload reduction
94. Combined digoxin‐molsidomine therapy in congestive heart failure following acute myocardial infarction
95. Effects of catecholamines on cardiovascular actions of molisdomine in anesthetized dogs
96. Effects of dihydroergotamine on hemodynamic molsidomine actions in anesthetized dogs
97. Double‐blind controlled trial of molsidomine in hypertension
98. Differential effects of dihydroergotamine on the circulatory actions of arterial and venous dilators in the rat
99. Effect of molsidomine on spontaneous ventricular fibrillation following myocardial ischemia and reperfusion in the dog
100. The activity of molsidomine in experimental models of ischemic cardiac disease
101. Myocardial reactive hyperemia
102. 2 in control of the coronary capillary reserve
103. Mapping of left ventricular blood flow with radioactive microspheres in experimental coronary artery occlusion
104. Regional myocardial blood flow during acute myocardial infarction in the conscious dog
105. Characterization of the “border zone” in acute regional ischemia in the dog
106. Radioautographic studies in experimental myocardial infarction. Profiles of ischemic blood flow and quantification of infarct size in relation to magnitude of ischemic zone
107. Pharmacologic‐ vs. ischemia‐induced coronary artery vasodilation
108. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris
109. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti‐thrombotic agents
110. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
111. Coronary venous thromboxane and prostacycline levels after coronary artery thrombosis in the dog
112. The role of platelets in thrombotic vascular disease
113. Effects of complete or partial occlusion of a coronary artery
114. Cardiac and coronary prostaglandin synthesis and function
115. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction
116. Thrombosis and ischaemic heart disease
117. Coronary vascular endothelium, spasm and reperfusion arrhythmias; experimental approaches
118. Effects of molsidomine and other NO‐containing vasodilators on cyclic GMP formation
119. Cyclic GMP as the mediator of molsidomine‐induced vasodilation
120. The effect of substituted sydnonimines on coronary smooth muscle relaxation and cyclic guanosine monophosphate levels
121. Inhibition of platelet function in vitro and in vivo by an antianginal drug (molsidomine)
122. Study on the effects of molsidomine, its metabolite, 3‐morpholino‐sydnonimine hydrochloride and carbocromen on platelet aggregation and thrombus formation
123. Laser‐induced thrombi in rat mesenteric vessels and antithrombotic drugs
124. The influence of molsidomine and its active metabolite SIN‐1 on fibrinolysis and platelet aggregation
125. Hemodynamic effects of molsidomine at rest and during submaximal and maximal exercise in patients with coronary artery disease limited by exertional angina pectoris
126. PAF‐acether antagonistic effects of molsidomine in vitro and in vivo
127. 2, and prostacyclin
128. Prostaglandins and ischemic heart disease
129. Prostaglandins and prostaglandin inhibitors in ischemic heart disease
130. Platelet function studies in coronary heart disease. VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia
131. 2) in 50 patients with myocardial infarction at young age
132. 2 in vasotonic angina pectoris. Evidence from direct measurements and inhibitor trial
133. 2 levels in patients with classic and variant angina pectoris
134. Thromboxane generation and platelet aggregation in survivals of myocardial infarction
135. Influences of cardiovascular drugs on leukotriene D4 action
136. Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy
137. Generation of a leukotriene‐like substance from porcine vascular and other tissues
138. Potent constriction of cat coronary arteries by hydroperoxides of arachidonic acid and its blockade by anti‐inflammatory agents
139. Increased adventitial mast cells in a patient with coronary spasm
140. Protection by carbo‐cromene and molsidomine against arrhythmias occurring during coronary artery occlusion and reperfusion in dogs
141. Molsidomine prevents post‐ischaemic ventricular fibrillation in dogs
142. Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise
143. Molsidomine, an effective long‐acting anti‐anginal drug
144. Pharmacodynamic principles of action of antianginal drugs